Corrigendum to "SAT-040 RENAL SAFETY OF DIRECT ACTING ANTIVIRAL DRUGS IN POST LIVER TRANSPLANT PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION" [Volume 5, Issue 3, Supplement, March 2020, Pages S18-S19].
「SAT-040 直接作用型抗病毒藥物於肝臟移植後慢性 C 型肝炎患者之腎臟安全性」更正啟事 [第5卷,第3期,增刊,2020年3月,S18-S19頁]
Kidney Int Rep 2025-06-09
A Comparison of Hospitalization Outcomes Between Peritoneal Dialysis and Home Hemodialysis Patients by Sex and Race.
依性別與種族比較腹膜透析與居家血液透析患者的住院結果
Kidney Int Rep 2025-06-09
The Utility of Myeloperoxidase Immunostaining to Characterize Immune Deposits in Patients With Crescentic Glomerulonephritis.
Myeloperoxidase 免疫染色於新月體腎小球腎炎患者中鑑別免疫沉積物的實用性
Kidney Int Rep 2025-06-09
The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A Nephropathy.
IgA腎病中針對β2-Spectrin與CBX3的IgA抗體之盛行率與特徵
Kidney Int Rep 2025-06-09
Interaction Between <i>Apolipoprotein L1</i> Genetic Risk and Neighborhood Socioeconomic Status for Kidney Outcomes in a United States Cohort.
Apolipoprotein L1 基因風險與社區社經地位對美國族群腎臟結局的交互影響
Kidney Int Rep 2025-06-09
<i>COL4A5</i>-p.Gly624Asp is the Predominant Variant in Europe Associated With a Mild Alport Syndrome Phenotype.
COL4A5-p.Gly624Asp 是歐洲最常見且與輕度 Alport Syndrome 表現相關的基因變異
Kidney Int Rep 2025-06-09
Corrigendum to "Outcomes of Living Kidney Donors Following Donor Nephrectomy in Aotearoa New Zealand" [Volume 10, Issue 3, March 2025, Pages 762-771].
「更正啟事:Aotearoa New Zealand 活體腎臟捐贈者於捐腎手術後之預後分析」【第10卷,第3期,2025年3月,頁762-771】
Kidney Int Rep 2025-06-09
The Retinal Vasculature and Risk of Age-Related GFR Decline - The Renal Iohexol Clearance Survey.
視網膜血管結構與年齡相關腎絲球過濾率(GFR)下降風險——Renal Iohexol Clearance 調查
Kidney Int Rep 2025-06-09